Investments & digital assets › F8949.A.X11
F8949.A.X11 · federal · F8949 line A.X11
Delmar Pharma (acquired 2025-02-27, sold 2025-04-15; proceeds 1,232.43, basis 1,199.55)
32.88
engine v3
not yet verified
How this number was built
R-8949-LOT One line per sale: proceeds minus basis plus adjustment. Broker basis is used as reported unless a supplemental statement for the same lot is matched.
Sources (6) — where the inputs came from
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 8 · field X11_desc · “Lot X11 description”
read as “Delmar Pharma” → Delmar Pharma
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 8 · field X11_acq · “Lot X11 date acquired”
read as “02/27/2025” → 2025-02-27
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 8 · field X11_sold · “Lot X11 date sold”
read as “04/15/2025” → 2025-04-15
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 8 · field X11_proceeds · “Lot X11 proceeds”
read as “1,232.43” → 1,232.43
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 8 · field X11_basis · “Lot X11 cost basis”
read as “1,199.55” → 1,199.55
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 8 · field X11_wash · “Lot X11 wash sale loss disallowed”
read as “0.00” → 0
99%
Flows into
History — nothing is overwritten
v1 · 2026-03-04: 32.88v2 · 2026-03-19: 32.88v3 · 2026-06-23: 32.88
Adjust this number
Evidence & discussion
Record how you verified it